RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
RenovoRx, Inc.NASDAQ: RNXT
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 25.0% from a year ago
Common stock stood at $5K at the end of Q1 FY2026, up 25.0% from a year earlier and up 25.0% from the prior quarter. Over 3 fiscal years it compounded at +58.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +25.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 4K USD
- Year-over-year change
- +100.0%
- 4-year CAGR
- +41.4%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4K | +100.0% |
| FY2024 | 2024-12-31 | 2K | +100.0% |
| FY2023 | 2023-12-31 | 1K | +0.0% |
| FY2022 | 2022-12-31 | 1K | +0.0% |
| FY2021 | 2021-12-31 | 1K | — |
Common Stock vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 common stock of $5K is the 2nd highest of the 6 companies compared; the peer median is $2.85K.
- Its year-over-year change of +25.0% is the 4th highest of 5, against a peer median of +48.3%.
- Common stock amounts to 0.0% of total assets for RNXT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.07K | +105.1% | +52.2% | 0.0% | |
| Mar 2026 | $5K | +25.0% | +58.7% | 0.0% | |
| Dec 2025 | $3K | +50.0% | -41.5% | 0.0% | |
| Mar 2026 | $2.85K | +46.5% | +49.4% | 0.0% | |
| Mar 2026 | $1.13K | +4.4% | +911.8% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RNXT) | $2.85K | +48.3% | +50.8% | 0.0% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.